Editas' mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company's five founders have published much of the foundational work that has elevated genome editing technology to a level where it can now be optimized and developed for therapeutic use. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/26/13 | $43,000,000 | Series A |
Flagship Ventures Partners Innovation Fund Polaris Partners Third Rock Ventures | undisclosed |
| 08/10/15 | $120,000,000 | Series B |
bng0 Cowen Investments Deerfield Management Company, L.P. EcoR1 Capital Fidelity Investments Flagship Ventures Polaris Partners T. Rowe Price Associates Third Rock Ventures Viking Global Investors | undisclosed |
